Mylan not interested in Icahn talks
94977
Mylan Laboratories Inc.&#39;s board Monday shunned an overture by financier Carl Icahn and said the company intends to remain independent while pursuing its proposed acquisition of King Pharmaceuticals, which Icahn opposes.
443606
Mylan Laboratories Inc. may have found the white knight it needs to check Carl Icahn&#39;s attempts to kill its $4 billion plan to acquire King Pharmaceuticals Inc.
655804
-- Mylan Laboratories  Inc.MYL.N on Wednesday said it was unlikely to complete its  $3.37 billion acquisition of King Pharmaceuticals Inc.KG.N at  the current price because of King's need to restate earnings.
613825
Billionaire financier Carl Icahn charged ahead on Monday with a $49 per share offer for New York office landlord Reckson Associates Realty Corp.  although his two partners withdrew from the bidding.
666716
The billionaire financier Carl C. Icahn offered yesterday to buy the generic drug maker Mylan Laboratories for about $5.4 billion in an effort to force Mylan to drop its proposed acquisition of King Pharmaceuticals.
406523
UBS Global Asset Management told Mylan Laboratories Inc. that Mylan&#39;s proposed acquisition of King Pharmaceuticals Inc. is dilutive to Mylan shareholders and not in the best interests of the investment firm&#39;s
131989
A Mylan Laboratories shareholder is suing the Canonsburg generic drug maker and its directors, saying they have failed their fiduciary obligations by not considering billionaire investor Carl Icahn&#39;s $20 per share offer for the company.
675107
The Canadian aluminum maker Alcan has denied a request by a rival, Alcoa, for further talks on Alcoaâs hostile $27.5 billion takeover bid.
543076
Financier Carl Icahn said Monday King Pharmaceutical Inc.&#39;s possible need to restate earnings reinforces his belief that an acquisition of King by Mylan Laboratories Inc.
331749
Not buying it. Megafinancier Carl Icahn has made it clear: He&#39;s still opposed to Mylan Laboratories&#39; (nyse: MYL - news - people ) proposed acquisition of King Pharmaceuticals (nyse: KG - news - people ). Despite
523584
New York real estate magnate Harry Macklowe backed away from a bid for Reckson Associates Realty Corp. , leaving former partner Carl Icahn alone to pursue an offer for the commercial real estate firm, a source familiar with the situation said on Sunday.
405872
New York real estate magnate Harry  Macklowe backed away from a bid for Reckson Associates Realty  Corp. , leaving former partner Carl Icahn alone to pursue  an offer for the commercial real estate firm, a source familiar  with the situation said on Sunday.
599973
Investor Carl Icahn issued a $20-per-share bid to acquire Mylan Laboratories Inc. on Friday and said &quot;at least&quot; three other potential buyers in the generic drug industry could offer more.
644960
It began in July: Mylan Laboratories (nyse: MYL - news - people ) announced it would bid $4 billion in stock for King Pharmaceuticals (nyse: KG - news - people ). Investors were less than unanimously thrilled
254001
Billionaire investor Carl Icahn, who is pressing for board changes at biotechnology company ImClone Systems Inc. , on Wednesday acknowledged that he rejected $36-per-share takeover offer for the company, saying the company is worth more.
362567
WASHINGTON An investment firm has told Mylan Laboratories that a proposed acquisition of King Pharmaceuticals is not in the best interests of investors.
15173
Reckson Associates Realty Corp.  said on Monday it would postpone a shareholder meeting until December 6 to give billionaire Carl Icahn and his partners more time to firm up financing for their $4.6 billion bid for the company.